TEST BANK
Basic and Clinical Pharmacology by Bertram Katzung
15th Edition
TEST BANK
, Test Bank For Basic and Clinical Pharmacology 15th Edition by Bertram Katzung
Table of Contents:
Section I: Basic principles
Chapter 1: Introduction: the nature of drugs & drug development & regulation
Chapter 2: Drug receptors & pharmacodynamics
Chapter 3: Pharmacokinetics & pharmacodynamics: rational dosing & the time course of
drug action
Chapter 4: Drug biotransformation
Chapter 5: Pharmacogenomics
Section II: Autonomic drugs
Chapter 6: Introduction to autonomic pharmacology
Chapter 7: Cholinoceptor-activating & cholinesterase-inhibiting drugs
Chapter 8: Cholinoceptor-blocking drugs
Chapter 9: Adrenoceptor agonists & sympathomimetic drugs
Chapter 10: Adrenoceptor antagonist drugs
Section III: Cardiovascular-renal drugs
Chapter 11: Antihypertensive agents
Chapter 12: Vasodilators & the treatment of angina pectoris
Chapter 13: Drugs used in heart failure
Chapter 14: Agents used in cardiac arrhythmias
Chapter 15: Diuretic agents
Section IV: Drugs with important actions on smooth muscle
Chapter 16: Histamine, serotonin, & the ergot alkaloids
Chapter 17: Vasoactive peptides
Chapter 18: The Eicosanoids: prostaglandins, thromboxanes, leukotrienes, & related
compounds
Chapter 19: Nitric oxide
Chapter 20: Drugs used in asthma
Section V: Drugs that act in the central nervous system
Chapter 21: Introduction to the pharmacology of cns drugs
Chapter 22: Sedative-hypnotic drugs
Chapter 23: The Alcohols
Chapter 24: Antiseizure drugs
Chapter 25: General anesthetics
Chapter 26: Local anesthetics
Chapter 27: Skeletal muscle relaxants
Chapter 28: Pharmacologic management of parkinsonism & other movement disorders
Chapter 29: Antipsychotic agents & lithium
Chapter 30: Antidepressant agents
Chapter 31: Opioid agonists & antagonists
Chapter 32: Drugs of abuse
,Section VI: Drugs used to treat diseases of the blood, inflammation, & gout
Chapter 33: Agents used in cytopenias; hematopoietic growth factors
Chapter 34: Drugs used in disorders of coagulation
Chapter 35: Agents used in dyslipidemia
Chapter 36: Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic
drugs, nonopioid analgesics, & drugs used in gout
Section VII: Endocrine drugs
Chapter 37: Hypothalamic & pituitary hormones
Chapter 38: Thyroid & antithyroid drugs
Chapter 39: Adrenocorticosteroids & adrenocortical antagonists
Chapter 40: The Gonadal hormones & inhibitors
Chapter 41: Pancreatic hormones & antidiabetic drugs
Chapter 42: Agents that affect bone mineral homeostasis
Section VIII: Chemotherapeutic drugs
Chapter 43: Beta-lactam & other cell wall- & membrane-active antibiotics
Chapter 44: Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, &
oxazolidinones
Chapter 45: Aminoglycosides & spectinomycin
Chapter 46: Sulfonamides, trimethoprim, & quinolones
Chapter 47: Antimycobacterial drugs
Chapter 48: Antifungal agents
Chapter 49: Antiviral agents
Chapter 50: Miscellaneous antimicrobial agents; disinfectants, antiseptics, & sterilants
Chapter 51: Clinical use of antimicrobial agents
Chapter 52: Antiprotozoal drugs
Chapter 53: Clinical pharmacology of the antihelminthic drugs
Chapter 54: Cancer chemotherapy
Chapter 55: Immunopharmacology
Section IX: Toxicology
Chapter 56: Introduction to toxicology: occupational & environmental
Chapter 57: Heavy metal intoxication & chelators
Chapter 58: Management of the poisoned patient
Section X: Special topics
Chapter 59: Special aspects of perinatal & pediatric pharmacology
Chapter 60: Special aspects of geriatric pharmacology
Chapter 61: Dermatologic pharmacology
Chapter 62: Drugs used in the treatment of gastrointestinal diseases
Chapter 63: Therapeutic & toxic potential of over-the-counter agents
Chapter 64: Dietary supplements & herbal medications
Chapter 65: Rational prescribing & prescription writing
Chapter 66: Important drug interactions & their mechanisms
,Bertram Katzung: Basic and Clinical Pharmacology 15th Edition
Chapter 1. Introduction: The Nature of Drugs & Drug Development & Regulation
Multiple Choice
1. A nurse working in radiology administers iodine to a patient who is having a
computed tomography (CT) scan. The nurse working on the oncology unit
administers chemotherapy to patients who have cancer. At the Public Health
Department, a nurse administers a measles-mumps-rubella (MMR) vaccine to
a 14-month-old child as a routine immunization. Which branch of
pharmacology best describes the actions of all three nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Feedback:
Pharmacology is the study of the biologic effects of chemicals. Nurses are
involved with clinical pharmacology or pharmacotherapeutics, which is a
branch of pharmacology that deals with the uses of drugs to treat, prevent,
and diagnose disease. The radiology nurse is administering a drug to help
diagnose a disease. The oncology nurse is administering a drug to help treat a
disease. Pharmacoeconomics includes any costs involved in drug therapy.
Pharmacodynamics involves how a drug affects the body and
pharmacokinetics is how the body acts on the body.
2. A physician has ordered intramuscular (IM) injections of morphine, a
narcotic, every 4 hours as needed for pain in a motor vehicle accident victim.
The nurse is aware this drug has a high abuse potential. Under what category
would morphine be classified?
A) Schedule I
B) Schedule II
WWW.THENURSINGMASTERY.COM
,C) Schedule fIII
D) Schedule fIV
Ans: B
Feedback:
Narcotics fwith fa fhigh fabuse fpotential fare fclassified fas fSchedule fII
fdrugs fbecause fof fsevere fdependence f liability. fSchedule f I fdrugs fhave
fhigh fabuse fpotential fand f no f accepted fmedical fuse. fSchedule f III fdrugs
fhave fa f lesser fabuse fpotential fthan fII fand fan faccepted fmedical fuse.
fSchedule fIV fdrugs fhave f low f abuse fpotential f and flimited fdependence
fliability.
3. When finvolved fin fphase fIII fdrug fevaluation fstudies, fwhat
fresponsibilities fwould fthe f nurse f have?
A) Working fwith fanimals fwho fare fgiven fexperimental f drugs
B) Choosing fappropriate fpatients fto fbe finvolved fin fthe fdrug f study
C) Monitoring fand fobserving fpatients fclosely ffor fadverse f effects
D) Conducting fresearch fto fdetermine feffectiveness fof fthe f drug
Ans: C
Feedback:
Phase fIII fstudies finvolve fuse fof fa fdrug fin fa fvast fclinical fpopulation fin
fwhich fpatients fare fasked fto frecord fany fsymptoms fthey fexperience
fwhile ftaking fthe fdrugs. fNurses fmay fbe fresponsible f for f helping f collect
fand fanalyze fthe f information fto fbe fshared fwith fthe fFood fand fDrug
fAdministration f(FDA) fbut fwould f not fconduct fresearch f independently
fbecause f nurses fdo f not fprescribe fmedications. fUse fof f animals f in fdrug
ftesting f is fdone f in f the fpreclinical f trials. fSelect fpatients fwho fare
finvolved f in fphase f II fstudies fto fparticipate f in fstudies fwhere f the
fparticipants f have fthe fdisease fthe fdrug f is f intended fto f treat. fThese
fpatients fare fmonitored fclosely f for fdrug f action f and fadverse f effects.
fPhase f I fstudies f involve f healthy f human f volunteers fwho f are fusually
fpaid ffor ftheir fparticipation. fNurses fmay f observe ffor fadverse f effects
fand f toxicity.
WWW.THENURSINGMASTERY.COM
,4. What fconcept fis fconsidered fwhen fgeneric fdrugs fare fsubstituted ffor
fbrand f name fdrugs?
A) Bioavailability
B) Critical fconcentration
C) Distribution
D) Half-life
Ans: A
Feedback:
Bioavailability fis fthe fportion fof fa fdose fof fa fdrug fthat freaches fthe
fsystemic fcirculation fand f is favailable fto f act f on fbody fcells. fBinders
fused fin fa fgeneric fdrug fmay f not fbe fthe fsame fas fthose fused f in fthe
fbrand f name fdrug. fTherefore, fthe fway f the fbody f breaks fdown fand
fuses fthe fdrug fmay fdiffer, fwhich f may feliminate fa fgeneric fdrug
fsubstitution. fCritical fconcentration fis fthe famount fof fa fdrug f that f is
fneeded fto fcause fa ftherapeutic feffect fand fshould fnot fdiffer fbetween
fgeneric fand fbrand f name f medications. fDistribution f is fthe fphase f of
fpharmacokinetics, fwhich f involves fthe fmovement f of fa fdrug f to fthe
fbodys ftissues fand f is fthe fsame fin fgeneric fand fbrand fname fdrugs. fA
fdrugs fhalf-life fis f the ftime f it ftakes ffor f the famount f of fdrug f to
fdecrease fto f half fthe fpeak f level, fwhich fshould f not f change fwhen
fsubstituting fa fgeneric f medication.
5. A fnurse fis fassessing fthe fpatients fhome fmedication fuse. fAfter flistening
fto fthe fpatient f list fcurrent f medications, fthe f nurse fasks fwhat fpriority
fquestion?
A) Do fyou ftake fany fgeneric fmedications?
B) Are fany fof fthese fmedications forphan f drugs?
C) Are fthese fmedications fsafe fto ftake fduring f pregnancy?
D) Do fyou ftake fany fover-the-counter f medications?
Ans: D
Feedback:
WWW.THENURSINGMASTERY.COM
, It fis fimportant ffor fthe fnurse fto fspecifically fquestion fuse fof fover-the-
counter fmedications fbecause fpatients fmay fnot fconsider fthem fimportant.
fThe fpatient f is funlikely fto fknow fthe fmeaning f of forphan fdrugs funless
fthey ftoo fare f health fcare fproviders. fSafety fduring fpregnancy, fuse f of fa
fgeneric fmedication, f or fclassification f of f orphan fdrugs fare fthings fthe
fpatient fwould fbe funable f to fanswer fbut fcould fbe ffound fin freference
fbooks fif fthe fnurse fwishes fto fresearch fthem.
6. After fcompleting fa fcourse fon fpharmacology ffor fnurses, fwhat fwill fthe
fnurse f know?
A) Everything fnecessary ffor fsafe fand feffective fmedication f administration
B) Current fpharmacologic ftherapy; fthe fnurse fwill fnot frequire
fongoing feducation f for f5 f years.
C) General fdrug finformation; fthe fnurse fcan fconsult fa fdrug fguide ffor
fspecific fdrug f information.
D) The fdrug factions fthat fare fassociated fwith feach
fclassification fof fmedication
Ans: C
Feedback:
After fcompleting fa fpharmacology fcourse fnurses fwill fhave fgeneral fdrug
finformation fneeded ffor fsafe fand feffective fmedication fadministration fbut
fwill f need fto fconsult fa fdrug fguide f for fspecific fdrug finformation fbefore
fadministering fany fmedication. fPharmacology f is fconstantly fchanging,
fwith f new fdrugs fentering fthe f market f and f new fuses ffor fexisting fdrugs
fidentified.
Continuing feducation fin fpharmacology fis fessential fto fsafe fpractice.
fNurses ftend fto fbecome ffamiliar fwith fthe fmedications fthey fadminister
fmost foften, fbut fthere fwill falways fbe fa f need fto f research fnew fdrugs
fand falso f those fthe f nurse f is f not f familiar fwith fbecause fno fnurse f knows
fall fmedications.
7. A fnurse fis finstructing fa fpregnant fpatient fconcerning fthe fpotential frisk
fto f her f fetus f from fa fPregnancy fCategory fB fdrug. fWhat fwould fthe
fnurse f inform f the fpatient?
A) Adequate fstudies fin fpregnant fwomen fhave fdemonstrated fthere fis
fno frisk fto fthe ffetus.
WWW.THENURSINGMASTERY.COM
Basic and Clinical Pharmacology by Bertram Katzung
15th Edition
TEST BANK
, Test Bank For Basic and Clinical Pharmacology 15th Edition by Bertram Katzung
Table of Contents:
Section I: Basic principles
Chapter 1: Introduction: the nature of drugs & drug development & regulation
Chapter 2: Drug receptors & pharmacodynamics
Chapter 3: Pharmacokinetics & pharmacodynamics: rational dosing & the time course of
drug action
Chapter 4: Drug biotransformation
Chapter 5: Pharmacogenomics
Section II: Autonomic drugs
Chapter 6: Introduction to autonomic pharmacology
Chapter 7: Cholinoceptor-activating & cholinesterase-inhibiting drugs
Chapter 8: Cholinoceptor-blocking drugs
Chapter 9: Adrenoceptor agonists & sympathomimetic drugs
Chapter 10: Adrenoceptor antagonist drugs
Section III: Cardiovascular-renal drugs
Chapter 11: Antihypertensive agents
Chapter 12: Vasodilators & the treatment of angina pectoris
Chapter 13: Drugs used in heart failure
Chapter 14: Agents used in cardiac arrhythmias
Chapter 15: Diuretic agents
Section IV: Drugs with important actions on smooth muscle
Chapter 16: Histamine, serotonin, & the ergot alkaloids
Chapter 17: Vasoactive peptides
Chapter 18: The Eicosanoids: prostaglandins, thromboxanes, leukotrienes, & related
compounds
Chapter 19: Nitric oxide
Chapter 20: Drugs used in asthma
Section V: Drugs that act in the central nervous system
Chapter 21: Introduction to the pharmacology of cns drugs
Chapter 22: Sedative-hypnotic drugs
Chapter 23: The Alcohols
Chapter 24: Antiseizure drugs
Chapter 25: General anesthetics
Chapter 26: Local anesthetics
Chapter 27: Skeletal muscle relaxants
Chapter 28: Pharmacologic management of parkinsonism & other movement disorders
Chapter 29: Antipsychotic agents & lithium
Chapter 30: Antidepressant agents
Chapter 31: Opioid agonists & antagonists
Chapter 32: Drugs of abuse
,Section VI: Drugs used to treat diseases of the blood, inflammation, & gout
Chapter 33: Agents used in cytopenias; hematopoietic growth factors
Chapter 34: Drugs used in disorders of coagulation
Chapter 35: Agents used in dyslipidemia
Chapter 36: Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic
drugs, nonopioid analgesics, & drugs used in gout
Section VII: Endocrine drugs
Chapter 37: Hypothalamic & pituitary hormones
Chapter 38: Thyroid & antithyroid drugs
Chapter 39: Adrenocorticosteroids & adrenocortical antagonists
Chapter 40: The Gonadal hormones & inhibitors
Chapter 41: Pancreatic hormones & antidiabetic drugs
Chapter 42: Agents that affect bone mineral homeostasis
Section VIII: Chemotherapeutic drugs
Chapter 43: Beta-lactam & other cell wall- & membrane-active antibiotics
Chapter 44: Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, &
oxazolidinones
Chapter 45: Aminoglycosides & spectinomycin
Chapter 46: Sulfonamides, trimethoprim, & quinolones
Chapter 47: Antimycobacterial drugs
Chapter 48: Antifungal agents
Chapter 49: Antiviral agents
Chapter 50: Miscellaneous antimicrobial agents; disinfectants, antiseptics, & sterilants
Chapter 51: Clinical use of antimicrobial agents
Chapter 52: Antiprotozoal drugs
Chapter 53: Clinical pharmacology of the antihelminthic drugs
Chapter 54: Cancer chemotherapy
Chapter 55: Immunopharmacology
Section IX: Toxicology
Chapter 56: Introduction to toxicology: occupational & environmental
Chapter 57: Heavy metal intoxication & chelators
Chapter 58: Management of the poisoned patient
Section X: Special topics
Chapter 59: Special aspects of perinatal & pediatric pharmacology
Chapter 60: Special aspects of geriatric pharmacology
Chapter 61: Dermatologic pharmacology
Chapter 62: Drugs used in the treatment of gastrointestinal diseases
Chapter 63: Therapeutic & toxic potential of over-the-counter agents
Chapter 64: Dietary supplements & herbal medications
Chapter 65: Rational prescribing & prescription writing
Chapter 66: Important drug interactions & their mechanisms
,Bertram Katzung: Basic and Clinical Pharmacology 15th Edition
Chapter 1. Introduction: The Nature of Drugs & Drug Development & Regulation
Multiple Choice
1. A nurse working in radiology administers iodine to a patient who is having a
computed tomography (CT) scan. The nurse working on the oncology unit
administers chemotherapy to patients who have cancer. At the Public Health
Department, a nurse administers a measles-mumps-rubella (MMR) vaccine to
a 14-month-old child as a routine immunization. Which branch of
pharmacology best describes the actions of all three nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Feedback:
Pharmacology is the study of the biologic effects of chemicals. Nurses are
involved with clinical pharmacology or pharmacotherapeutics, which is a
branch of pharmacology that deals with the uses of drugs to treat, prevent,
and diagnose disease. The radiology nurse is administering a drug to help
diagnose a disease. The oncology nurse is administering a drug to help treat a
disease. Pharmacoeconomics includes any costs involved in drug therapy.
Pharmacodynamics involves how a drug affects the body and
pharmacokinetics is how the body acts on the body.
2. A physician has ordered intramuscular (IM) injections of morphine, a
narcotic, every 4 hours as needed for pain in a motor vehicle accident victim.
The nurse is aware this drug has a high abuse potential. Under what category
would morphine be classified?
A) Schedule I
B) Schedule II
WWW.THENURSINGMASTERY.COM
,C) Schedule fIII
D) Schedule fIV
Ans: B
Feedback:
Narcotics fwith fa fhigh fabuse fpotential fare fclassified fas fSchedule fII
fdrugs fbecause fof fsevere fdependence f liability. fSchedule f I fdrugs fhave
fhigh fabuse fpotential fand f no f accepted fmedical fuse. fSchedule f III fdrugs
fhave fa f lesser fabuse fpotential fthan fII fand fan faccepted fmedical fuse.
fSchedule fIV fdrugs fhave f low f abuse fpotential f and flimited fdependence
fliability.
3. When finvolved fin fphase fIII fdrug fevaluation fstudies, fwhat
fresponsibilities fwould fthe f nurse f have?
A) Working fwith fanimals fwho fare fgiven fexperimental f drugs
B) Choosing fappropriate fpatients fto fbe finvolved fin fthe fdrug f study
C) Monitoring fand fobserving fpatients fclosely ffor fadverse f effects
D) Conducting fresearch fto fdetermine feffectiveness fof fthe f drug
Ans: C
Feedback:
Phase fIII fstudies finvolve fuse fof fa fdrug fin fa fvast fclinical fpopulation fin
fwhich fpatients fare fasked fto frecord fany fsymptoms fthey fexperience
fwhile ftaking fthe fdrugs. fNurses fmay fbe fresponsible f for f helping f collect
fand fanalyze fthe f information fto fbe fshared fwith fthe fFood fand fDrug
fAdministration f(FDA) fbut fwould f not fconduct fresearch f independently
fbecause f nurses fdo f not fprescribe fmedications. fUse fof f animals f in fdrug
ftesting f is fdone f in f the fpreclinical f trials. fSelect fpatients fwho fare
finvolved f in fphase f II fstudies fto fparticipate f in fstudies fwhere f the
fparticipants f have fthe fdisease fthe fdrug f is f intended fto f treat. fThese
fpatients fare fmonitored fclosely f for fdrug f action f and fadverse f effects.
fPhase f I fstudies f involve f healthy f human f volunteers fwho f are fusually
fpaid ffor ftheir fparticipation. fNurses fmay f observe ffor fadverse f effects
fand f toxicity.
WWW.THENURSINGMASTERY.COM
,4. What fconcept fis fconsidered fwhen fgeneric fdrugs fare fsubstituted ffor
fbrand f name fdrugs?
A) Bioavailability
B) Critical fconcentration
C) Distribution
D) Half-life
Ans: A
Feedback:
Bioavailability fis fthe fportion fof fa fdose fof fa fdrug fthat freaches fthe
fsystemic fcirculation fand f is favailable fto f act f on fbody fcells. fBinders
fused fin fa fgeneric fdrug fmay f not fbe fthe fsame fas fthose fused f in fthe
fbrand f name fdrug. fTherefore, fthe fway f the fbody f breaks fdown fand
fuses fthe fdrug fmay fdiffer, fwhich f may feliminate fa fgeneric fdrug
fsubstitution. fCritical fconcentration fis fthe famount fof fa fdrug f that f is
fneeded fto fcause fa ftherapeutic feffect fand fshould fnot fdiffer fbetween
fgeneric fand fbrand f name f medications. fDistribution f is fthe fphase f of
fpharmacokinetics, fwhich f involves fthe fmovement f of fa fdrug f to fthe
fbodys ftissues fand f is fthe fsame fin fgeneric fand fbrand fname fdrugs. fA
fdrugs fhalf-life fis f the ftime f it ftakes ffor f the famount f of fdrug f to
fdecrease fto f half fthe fpeak f level, fwhich fshould f not f change fwhen
fsubstituting fa fgeneric f medication.
5. A fnurse fis fassessing fthe fpatients fhome fmedication fuse. fAfter flistening
fto fthe fpatient f list fcurrent f medications, fthe f nurse fasks fwhat fpriority
fquestion?
A) Do fyou ftake fany fgeneric fmedications?
B) Are fany fof fthese fmedications forphan f drugs?
C) Are fthese fmedications fsafe fto ftake fduring f pregnancy?
D) Do fyou ftake fany fover-the-counter f medications?
Ans: D
Feedback:
WWW.THENURSINGMASTERY.COM
, It fis fimportant ffor fthe fnurse fto fspecifically fquestion fuse fof fover-the-
counter fmedications fbecause fpatients fmay fnot fconsider fthem fimportant.
fThe fpatient f is funlikely fto fknow fthe fmeaning f of forphan fdrugs funless
fthey ftoo fare f health fcare fproviders. fSafety fduring fpregnancy, fuse f of fa
fgeneric fmedication, f or fclassification f of f orphan fdrugs fare fthings fthe
fpatient fwould fbe funable f to fanswer fbut fcould fbe ffound fin freference
fbooks fif fthe fnurse fwishes fto fresearch fthem.
6. After fcompleting fa fcourse fon fpharmacology ffor fnurses, fwhat fwill fthe
fnurse f know?
A) Everything fnecessary ffor fsafe fand feffective fmedication f administration
B) Current fpharmacologic ftherapy; fthe fnurse fwill fnot frequire
fongoing feducation f for f5 f years.
C) General fdrug finformation; fthe fnurse fcan fconsult fa fdrug fguide ffor
fspecific fdrug f information.
D) The fdrug factions fthat fare fassociated fwith feach
fclassification fof fmedication
Ans: C
Feedback:
After fcompleting fa fpharmacology fcourse fnurses fwill fhave fgeneral fdrug
finformation fneeded ffor fsafe fand feffective fmedication fadministration fbut
fwill f need fto fconsult fa fdrug fguide f for fspecific fdrug finformation fbefore
fadministering fany fmedication. fPharmacology f is fconstantly fchanging,
fwith f new fdrugs fentering fthe f market f and f new fuses ffor fexisting fdrugs
fidentified.
Continuing feducation fin fpharmacology fis fessential fto fsafe fpractice.
fNurses ftend fto fbecome ffamiliar fwith fthe fmedications fthey fadminister
fmost foften, fbut fthere fwill falways fbe fa f need fto f research fnew fdrugs
fand falso f those fthe f nurse f is f not f familiar fwith fbecause fno fnurse f knows
fall fmedications.
7. A fnurse fis finstructing fa fpregnant fpatient fconcerning fthe fpotential frisk
fto f her f fetus f from fa fPregnancy fCategory fB fdrug. fWhat fwould fthe
fnurse f inform f the fpatient?
A) Adequate fstudies fin fpregnant fwomen fhave fdemonstrated fthere fis
fno frisk fto fthe ffetus.
WWW.THENURSINGMASTERY.COM
